Potential Role of 68Ga-NOTA-Duramycin PET/CT Imaging for Early Response Evaluation in a Lymphoma Patient: A Case Report.

Autor:	Kaur G; From the Departments of Nuclear Medicine., Shukla J; From the Departments of Nuclear Medicine., Sood A; From the Departments of Nuclear Medicine., Prakash G; Internal Medicine., Krishnaraju VS; From the Departments of Nuclear Medicine., Rana N; From the Departments of Nuclear Medicine., Pandey S; From the Departments of Nuclear Medicine., Singh H; From the Departments of Nuclear Medicine., Kumar R; From the Departments of Nuclear Medicine., Bal A; Histopathology Postgraduate Institute of Medical Education and Research, Chandigarh, India., Mittal BR; From the Departments of Nuclear Medicine.
Jazyk:	angličtina
Zdroj:	Clinical nuclear medicine [Clin Nucl Med] 2023 Jan 01; Vol. 48 (1), pp. e19-e21. Date of Electronic Publication: 2022 Oct 26.
DOI:	10.1097/RLU.0000000000004462
Abstrakt:	Abstract: Duramycin, a 19 amino acids peptide, is known for its potential to target phosphatidylethanolamine. During cell death (apoptosis), rearrangement of membrane phospholipids results in the externalization of phosphatidylethanolamine to the outer leaflet of the cell membrane, which can be imaged using 68Ga-NOTA-duramycin. We report 68Ga-NOTA-duramycin imaging in a 50-year-old man with biopsy-proven diffuse large B-cell lymphoma planned for anthracycline-based chemotherapy. 68Ga-NOTA-duramycin PET/CT imaging along with 18F-FDG PET/CT was performed before and after 2 cycles of chemotherapy. The tracer avidity in interim 68Ga-NOTA-duramycin PET/CT showed its diagnostic potential to assess early response to chemotherapy. Competing Interests: Conflicts of interest and sources of funding: The authors declare that they have no conflicts of interest. This study was funded by the DST INSPIRE Fellowship, New Delhi, India (application reference no. DST/INSPIRE/03/2016/002649). (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu